Sultamicillin: Difference between revisions

	WikiDoc Resources for Sultamicillin
Articles
Most recent articles on Sultamicillin Most cited articles on Sultamicillin Review articles on Sultamicillin Articles on Sultamicillin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sultamicillin Images of Sultamicillin Photos of Sultamicillin Podcasts & MP3s on Sultamicillin Videos on Sultamicillin
Evidence Based Medicine
Cochrane Collaboration on Sultamicillin Bandolier on Sultamicillin TRIP on Sultamicillin
Clinical Trials
Ongoing Trials on Sultamicillin at Clinical Trials.gov Trial results on Sultamicillin Clinical Trials on Sultamicillin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sultamicillin NICE Guidance on Sultamicillin NHS PRODIGY Guidance FDA on Sultamicillin CDC on Sultamicillin
Books
Books on Sultamicillin
News
Sultamicillin in the news Be alerted to news on Sultamicillin News trends on Sultamicillin
Commentary
Blogs on Sultamicillin
Definitions
Definitions of Sultamicillin
Patient Resources / Community
Patient resources on Sultamicillin Discussion groups on Sultamicillin Patient Handouts on Sultamicillin Directions to Hospitals Treating Sultamicillin Risk calculators and risk factors for Sultamicillin
Healthcare Provider Resources
Symptoms of Sultamicillin Causes & Risk Factors for Sultamicillin Diagnostic studies for Sultamicillin Treatment of Sultamicillin
Continuing Medical Education (CME)
CME Programs on Sultamicillin
International
Sultamicillin en Espanol Sultamicillin en Francais
Business
Sultamicillin in the Marketplace Patents on Sultamicillin
Experimental / Informatics
List of terms related to Sultamicillin

Sultamicillin
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	J01CR04 (WHO) ;
Identifiers
	IUPAC name [(2R)-3,3-Dimethyl-4,4,7-trioxy-4λ6-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxymethyl(2R)-6-{[(2S)-2-amino-2-phenyl-acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate;
CAS Number	76497-13-7 ;
PubChem CID	444022;
ChemSpider	392048 ;
UNII	65DT0ML581;
KEGG	D05972 ;
ChEBI	CHEBI:51770 ;
ChEMBL	ChEMBL506110 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C25H30N4O9S2
Molar mass	594.659 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(OCOC(=O)[C@@H]2N1C(=O)C[C@H]1S(=O)(=O)C2(C)C)[C@@H]4N5C(=O)[C@@H](NC(=O)[C@@H](c3ccccc3)N)[C@H]5SC4(C)C;
	InChI InChI=1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1 ; Key:OPYGFNJSCUDTBT-PMLPCWDUSA-N ;
(what is this?) (verify)

VisualWikitext

Revision as of 14:09, 9 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sultamicillin is an oral form of the antibiotic combination (codrug or mutual prodrug) ampicillin/sulbactam. It contains esterified ampicillin and sulbactam and is marketed under a number of trade names, including Saltum from Morepen Lab and Unasyn from Pfizer.

The pharmacokinetic properties of sultamicillin are improved compared to a combination of ampicillin and sulbactam. Sultamicillin increases the absorption and decreases the chances of diarrhea and dysentery. The inclusion of sulbactam extends ampicillin's spectrum of action to beta-lactamase producing strains of bacteria. Oral sulbactam with parenteral form provides a regimen of continuous sulbactam therapy throughout the treatment, resulting in better clinical results.

Chemical evaluation

Sultamicillin is a mutual prodrug of ampicillin and sulbactam. Ampicillin, a semi-synthetic orally active broad spectrum antibiotic, is linked via a methylene group with a beta-lactamase inhibitor. Sultamicillin is chemically oxymethyl penicillinate sulfone ester of ampicillin.

Mechanism of action

After absorption, sultamicillin releases ampicillin and sulbactam into the system, so all the antibacterial efficacy of sultamicillin is due to ampicillin and sulbactam. Ampicillin exerts antibacterial activity against sensitive organisms by inhibiting biosynthesis of cell wall mucopeptide where as sulbactam irreversibly inhibits most important beta-lactamases that occur in resistant strains.

Indications

Indications for sultamicillin include:

Skin and soft tissue infections - furuncles, carbuncles, cellulitis, paronychia, impetigo contagiosa, diabetic foot ulcers and abscesses caused by Staphylococcus aureus and Streptococcus pyogenes.
Upper respiratory tract infections - pharyngitis and tonsillitis caused by S. pyogenes and S. aureus. Acute and chronic sinusitis caused by S. aureus, S. pneumoniae, H. influenzae and S. progenies. Otis media, particularly suppurative otis media, with or without mastoiditis antrum.
Lower respiratory tract infections - bacterial pneumonias, bronchitis, bronchiestasis caused by S. pneumoniae, H. influenzae, Staphylococcus aureus and S. progenies. Acute exacerbations of COPD.
Urinary tract infections - pyelonephritis, cystitis caused by Escherichia coli, Proteus mirabilis, Klebsiella, Enterobacter and Staphylococcus aureus.
Surgical infections - prophylaxis and treatment of surgical site infections, peri-operative prophylaxis in orthopaedic and cardiovascular surgery.
Gynecological infections - Caused by beta-lactamase producing strains of E. coli and Bacteroides sp. (including B. fragilis).
Infections of the gastrointestinal tract - Bacterial esophagitis, treatment of H. pylori infections as a part of MDT in ulcer management.

References

Template:Nofootnotes

Singh, G.S. (2004). "Beta-lactams in the new millennium. Part-II: Cephems, oxacephems, penams and sulbactam". Mini Reviews in Medicinal Chemistry. 4 (1): 93–109. doi:10.2174/1389557043487547. PMID 14754446.

@@ Line 1: / Line 1: @@
-{{drugbox |
+{{Drugbox
-| IUPAC_name = [(2''R'')-3,3-dimethyl-4,4,7-trioxo-4λ<sup>6</sup>-thia-1-azabicyclo<br>[3.2.0]heptane-2-carbonyl]oxymethyl(2''R'')-6-{[(2''S'')-<br>2-amino-2-phenyl-acetyl]amino}-3,3-dimethyl-7-oxo-<br>4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
+| Verifiedfields = changed
-| image = Sultamicillin.svg
+| Watchedfields = changed
+| verifiedrevid = 470474605
+| Verified fields = changed
+| verified revid = 470474605
+| IUPAC_name = [(2''R'')-3,3-Dimethyl-4,4,7-trioxy-4λ<sup>6</sup>-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxymethyl(2''R'')-6-{[(2''S'')-2-amino-2-phenyl-acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
+| image = Sultamicillin.png
+<!--Clinical data-->
+| trade name =
+| Drugs.com = {{drugs.com|international|sultamicillin}}
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category =
+| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
+| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
+| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
+| legal_status =
+| routes_of_administration = Oral
+<!--Pharmacokinetic data-->
+| bio-availability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|changed|??}}
 | CAS_number = 76497-13-7
 | ATC_prefix = J01
 | ATC_suffix = CR04
-| PubChem = 53512
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 506110
+| PubChem = 444022
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank =
-| C = 25 | H = 30 | N = 4 | O = 9 | S = 2
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 392048
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = 65DT0ML581
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D05972
+| ChEBI_Ref = {{ebicite|correct|EBI}}
+| ChEBI = 51770
+<!--Chemical data-->
+| C=25 | H=30 | N=4 | O=9 | S=2
 | molecular_weight = 594.659 g/mol
-| bioavailability =
+| smiles = O=C(OCOC(=O)[C@@H]2N1C(=O)C[C@H]1S(=O)(=O)C2(C)C)[C@@H]4N5C(=O)[C@@H](NC(=O)[C@@H](c3ccccc3)N)[C@H]5SC4(C)C
-| protein_bound =
+| InChI = 1/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1
-| metabolism =
+| InChIKey = OPYGFNJSCUDTBT-PMLPCWDUBA
-| elimination_half-life =
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
-| excretion =
+| StdInChI = 1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1
-| pregnancy_AU =  <!-- A / B1 / B2 / B3 / C / D / X -->
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
-| pregnancy_US =  <!-- A / B            / C / D / X -->
+| StdInChIKey = OPYGFNJSCUDTBT-PMLPCWDUSA-N
-| pregnancy_category =
-| legal_AU =  <!-- Unscheduled / S2 / S3 / S4  / S8 -->
-| legal_CA =  <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| legal_UK =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| legal_US =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
-| legal_status =
-| routes_of_administration = Oral
 }}
+__Notoc__
 {{SI}}
+{{CMG}}
+==Overview==
+'''Sultamicillin''' is an oral form of the antibiotic combination ([[codrug]] or mutual [[prodrug]]) [[ampicillin/sulbactam]]. It contains [[ester]]ified [[ampicillin]] and [[sulbactam]] and is marketed under a number of trade names, including '''Saltum''' from Morepen Lab and '''Unasyn''' from [[Pfizer]].
-'''Sultamicillin''' is an oral form of the antibiotic combination [[ampicillin/sulbactam]]. It contains [[ester|esterified]] [[ampicillin]] and [[sulbactam]] and is marketed under a number of trade names, including '''Ampictam''' and '''Unacid'''.
+The pharmacokinetic properties of sultamicillin are improved compared to a combination of ampicillin and sulbactam.  Sultamicillin increases the absorption and decreases the chances of [[diarrhea]] and [[dysentery]]. The inclusion of sulbactam extends ampicillin's spectrum of action to [[beta-lactamase]] producing strains of bacteria. Oral sulbactam with parenteral form provides a regimen of continuous sulbactam therapy throughout the treatment, resulting in better clinical results.
-== References ==
+==Chemical evaluation==
-*Singh GS. ''Beta-lactams in the new millennium. Part-II: cephems, oxacephems, penams and sulbactam.''
+Sultamicillin is a mutual prodrug of ampicillin and sulbactam. Ampicillin, a [[semi-synthetic]] orally active broad spectrum antibiotic, is linked via a [[methylene group]] with a beta-lactamase inhibitor. Sultamicillin is chemically oxymethyl penicillinate sulfone ester of ampicillin.
-Mini Rev Med Chem. 2004 Jan;4(1):93-109. Review.
-PMID 14754446
-{{PenicillinAntiBiotics}}
+==Mechanism of action==
+After absorption, sultamicillin releases ampicillin and sulbactam into the system, so all the antibacterial efficacy of sultamicillin is due to ampicillin and sulbactam. Ampicillin exerts antibacterial activity against sensitive organisms by inhibiting biosynthesis of cell wall [[mucopeptide]] where as sulbactam irreversibly inhibits most important beta-lactamases that occur in resistant strains.
-[[Category:Beta-lactam antibiotics]]
+==Indications==
+[[Indication (medicine)|Indication]]s for sultamicillin include:
+* Skin and soft tissue infections - [[furuncle]]s, [[carbuncle]]s, [[cellulitis]], [[paronychia]], [[impetigo contagiosa]], [[diabetic foot ulcer]]s and abscesses caused by ''[[Staphylococcus aureus]]'' and ''[[Streptococcus pyogenes]]''.
+* [[Upper respiratory tract infection]]s - [[pharyngitis]] and [[tonsillitis]] caused by ''[[S. pyogenes]]'' and ''S. aureus''. Acute and chronic sinusitis caused by ''S. aureus'', ''[[S. pneumoniae]]'', ''[[H. influenzae]]'' and ''S. progenies''. [[Otis media]], particularly suppurative otis media, with or without [[mastoiditis antrum]].
+* [[Lower respiratory tract infection]]s - [[bacterial pneumonias]], [[bronchitis]], [[bronchiestasis]] caused by ''S. pneumoniae'', ''H. influenzae'', ''Staphylococcus aureus'' and ''S. progenies''. Acute exacerbations of [[COPD]].
+* [[Urinary tract infection]]s - [[pyelonephritis]], [[cystitis]] caused by ''[[Escherichia coli]]'', ''[[Proteus mirabilis]]'', ''[[Klebsiella]]'', ''[[Enterobacter]]'' and ''Staphylococcus aureus''.
+* Surgical infections - prophylaxis and treatment of surgical site infections, peri-operative prophylaxis in orthopaedic and cardiovascular surgery.
+* Gynecological infections - Caused by beta-lactamase producing strains of ''E. coli'' and ''[[Bacteroides]]'' sp. (including ''[[B. fragilis]]'').
+* Infections of the [[gastrointestinal tract]] - Bacterial [[esophagitis]], treatment of ''[[H. pylori]]'' infections as a part of MDT in ulcer management.
+==References==
+{{nofootnotes|date=September 2014}}
+* {{cite journal | doi =10.2174/1389557043487547 | pmid = 14754446| year = 2004| author1 = Singh| first1 = G.S.| title = Beta-lactams in the new millennium. Part-II: Cephems, oxacephems, penams and sulbactam| journal = Mini Reviews in Medicinal Chemistry| volume = 4| issue = 1| pages = 93–109}}
+{{Cell wall disruptive antibiotics}}
-[[de:Sultamicillin]]
+[[Category:Drug]]
-[[th:ซัลทามิซิลลิน]]
-[[tr:Sultamisiln]]
-{{WH}}
+[[Category:Beta-lactam antibiotics]]
-{{WS}}

Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	J01CR04 (WHO)
Identifiers
IUPAC name [(2R)-3,3-Dimethyl-4,4,7-trioxy-4λ⁶-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxymethyl(2R)-6-{[(2S)-2-amino-2-phenyl-acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
CAS Number	76497-13-7^N
PubChem CID	444022
ChemSpider	392048^Y
UNII	65DT0ML581
KEGG	D05972^Y
ChEBI	CHEBI:51770^Y
ChEMBL	ChEMBL506110^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₅H₃₀N₄O₉S₂
Molar mass	594.659 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(OCOC(=O)[C@@H]2N1C(=O)C[C@H]1S(=O)(=O)C2(C)C)[C@@H]4N5C(=O)[C@@H](NC(=O)[C@@H](c3ccccc3)N)[C@H]5SC4(C)C
InChI InChI=1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1^Y Key:OPYGFNJSCUDTBT-PMLPCWDUSA-N^Y
^NY (what is this?) (verify)